Skip to main content

Table 1 Clinical data of mTLE and Control patients

From: Protein expression profiling of inflammatory mediators in human temporal lobe epilepsy reveals co-activation of multiple chemokines and cytokines

Patient group

Age

Sex

Pathology/COD

Tissue used

Seizure frequency

iEcOG spikes

Anti-epileptic drugs

Engel score (1 yr)

1) Control

73

F

subdural hematoma

HC

NA

NA

NA

NA

2) Control

58

M

unknown. ALS patient

HC & CX

NA

NA

NA

NA

3) Control

62

M

unknown, non-demented control

HC & CX

NA

NA

NA

NA

4) Control

94

F

CVA

HC & CX

NA

NA

NA

NA

5) Control

71

M

pancreas carcinoma

HC & CX

NA

NA

NA

NA

6) Control

64

F

respiratory failure

HC & CX

NA

NA

NA

NA

7) Control

70

M

sepsis with broncopneumonia

HC

NA

NA

NA

NA

8) Control

50

F

metastasized broncocarcinoma

HC & CX

NA

NA

NA

NA

9) Control

48

M

DMT I induced organ failure

HC

NA

NA

NA

NA

10) Control

74

M

pulmonary carcinoma

HC & CX

NA

NA

NA

NA

11) Control

62

F

renal carcinoma (euthanasia)

CX

NA

NA

NA

NA

12) Control

93

F

heart failure

CX

NA

NA

NA

NA

13) Control

92

F

cachexia/dehydration

CX

NA

NA

NA

NA

14) non-HS

45

M

W0, FCD type1 to 2A in cortex

HC

6

CX

LTG, PHT

1A

15) non-HS

46

F

W0, MCD type 1 in cortex

HC

12

CX

CBZ, VPA

1A

16) non-HS

46

M

W0, epilepsy after head trauma

HC

90

HC & CX

CBZ, VPA, TPR

1B

17) non-HS

42

F

W0, DNT WHO grade I

HC & CX

1

CX

CBZ, LTG, LEV

1A

18) non-HS

34

F

W0, cortical cavernoma

HC

1.5

HC & CX

CBZ

1A

19) non-HS

40

F

W0, MCD type 1 in cortex

HC

8 ( C )

HC & CX

LEV, LTG, CBZ

1A

20) non-HS

43

F

W0, therapy resistant epilepsy

HC & CX

40 ( C )

HC & CX

PHT, LTG

1A

21) non-HS

47

M

W0, therapy resistant epilepsy

HC

30

HC

CBZ, VPA, LTG, LEV

3A

22) non-HS

28

M

W0, MCD type 1 in cortex

HC

60

HC & CX

CBZ, TPR.

1A

23) non-HS

54

M

W0, ganglioglioma WHO grade I

HC & CX

1.5

HC & CX

OXC, LTG, CLO

1A

24) non-HS

30

M

W0, therapy resistant epilepsy

CX

8

HC & CX

OXC, LEV, CLO

1A

25) non-HS

37

F

W0, therapy resistant epilepsy

CX

1

not measured

LTG, CLO

1A

26) non-HS

61

M

W0, therapy resistant epilepsy

CX

5.5

HC & CX

PHT, CBZ

2A

27) non-HS

19

M

W0, ganglioglioma WHO grade II

CX

1

None

VPA, LEV

1A

28) non-HS

27

F

W0, therapy resistant epilepsy

CX

16

HC & CX

LEV

1A

29) non-HS

46

M

W0, cavernoma in uncus

CX

60

HC

CBZ, VPA, OXC, LEV, LTG

1A

30) non-HS

44

M

W0, therapy resistant epilepsy

CX

18

HC & CX

TPR, OXC

1A

31) HS

41

M

MTS W4

HC & CX

12

not measured

PHT, CLO, CBZ, LTG

1A

32) HS

44

F

MTS W2

HC

8 ( C )

not measured

CBZ, OXC, CLO

1A

33) HS

41

M

MTS W4

HC

3

not measured

CBZ

1A

34) HS

52

F

MTS W4

HC & CX

10

not measured

CBZ, CLO, DZP

2D

35) HS

50

M

MTS W4

HC

18

not measured

CBZ, GBP

2A

36) HS

36

F

MTS W4

HC & CX

2

not measured

OXC, LZP

no info

37) HS

42

M

MTS W4

HC & CX

2

not measured

LEV, LTG

2A

38) HS

36

M

MTS W4

HC & CX

10

HC & CX

OXC, PGB

1B

39) HS

49

F

MTS W4

HC

8 ( C )

not measured

OXC, CLO

1A

40) HS

42

F

MTS W4

HC

4.5

not measured

LEV, LTG, PBT

1A

41) HS

36

M

MTS W4

CX

5

not measured

PGB, LTG

1A

42) HS

34

F

MTS W4

CX

10 ( C )

HC & CX

LTG, CBZ, VPA,CLO

2A

43) HS

49

M

MTS W3

CX

1

None

LTG, CBZ, CLO

1A

44) HS

45

M

MTS W4

CX

0.5

not measured

GBP, LTG

1A

45) HS

48

M

MTS W4

CX

3.5

not measured

CBZ, LTG, VPA

1A

  1. Hippocampal (HC) and neocortical (CX) homogenates were prepared from tissue of the listed patients as indicated in column 5. All epilepsy patients suffered therapy resistant epilepsy, any additional pathologies are listed in column 4. Seizure frequencies are listed as an average of monthly activity, patients who suffered clustered attacks are marked (C). iEcOG spikes indicate epileptic spike activity detected by iEcOG at surgery. Engel scores were recorded 1 year after surgery [35]. Abbreviations: ALS amyotrophic lateral sclerosis, CBZ Carbamazepine, COD cause of death, CLO Clobazam, CVA cerebrovascular accident, CX temporal neocortex, DMT I diabetes mellitus type I, DNT Dysembryonic neuroepithelial tumor, DZP diazepam, FCD focal cortical dysplasia, GBP Gabapentin, HC hippocampus, HS hippocampal sclerosis, iEcOG intraoperative electrocorticography, LEV Levetiracetam, LTG Lamotrigine, LZP Lorazepam, MCD malformation of cortical development, MTS mesial temporal sclerosis, NA not applicable, OXC Oxcarbazepine, PBT Phenobarbital, PGB Pregabaline, PHT Phenytoin, PMD post mortem delay, RIN RNA integrity number, TPR Topiramate; VPA Valproinic acid, W0 till 4 Wyler score, WHO grade world health organization grading scale of malignancy.